Pathology: mHNSCC - L2 - all population; mHNSCC - L2 - PDL1 negative;
| mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 negative | |||
| EAGLE (DT vs ICC), 2019 | CONDOR (DT vs D ; PDL1 TC<25%), 2019 | CONDOR (DT vs T ; PDL1 TC<25%), 2019 | ||
| durvalumab plus tremelimumab | 3 | T1 | T1 | T1 |
| Standard of Care (SoC) | 0 | T0 | ||
| durvalumab alone | 0 | T0 | ||
| tremelimumab | 0 | T0 |